Influenza antigen delivery vectors and constructs
The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.
1. A vector-antigen construct comprising:
an antigenic influenza peptide sequence covalently attached to a vector, wherein the vector is of structure C m X n —C y H x -(Sp)-R, wherein m=3 to 30, n<=2m+1, y=0 to 15, x<=2y, (m+y)=3 to 30, Sp is an optional chemical spacer moiety, R is the antigenic influenza peptide and X is selected from a fluorine, chlorine, bromine or iodine, and wherein the antigenic influenza peptide is up to 40 amino acids in length and comprises any one of SEQ ID NOs: 1 to 65.
2. The vector-antigen construct of claim 1 , wherein the antigenic influenza peptide comprises an amino acid sequence of any one of SEQ ID NOs: 1, 4, 17, 18, 32 or 35.
3. The vector-antigen construct of claim 1 , wherein the vector is of structure C m F n —C y H x -(Sp)-R, wherein m=3 to 30, n<=2m+1, y=0 to 15, x<=2y, (m+y)=3 to 30, Sp is an optional chemical spacer moiety and R is the antigenic influenza peptide.
4. The vector-antigen construct of claim 1 , wherein the vector comprises structure
where Sp is an optional chemical spacer moiety and R is the antigenic influenza peptide.
5. A pharmaceutical composition for intracellular delivery of an antigen, the composition comprising an antigenic influenza peptide sequence covalently attached to a vector, wherein the vector is of structure C m X n —C y H x -(Sp)-R, wherein m=3 to 30, n<=2m+1, y=0 to 15, x<=2y, (m+y)=3 to 30, Sp is an optional chemical spacer moiety, R is the antigenic influenza peptide and X is selected from a fluorine, chlorine, bromine or iodine, and wherein the antigenic influenza peptide is up to 40 amino acids in length and comprises any one of SEQ ID NOs: 1 to 65.
6. The composition of claim 5 , wherein the vector is of structure C m F n —C y H x -(Sp)-R, wherein m=3 to 30, n<=2m+1, y=0 to 15, x<=2y, (m+y)=3 to 30, Sp is an optional chemical spacer moiety and R is the antigenic influenza peptide.
7. The composition of claim 5 , wherein the vector comprises structure
where Sp is an optional chemical spacer moiety and R is the antigenic influenza peptide.
8. The composition of claim 5 , wherein the composition comprises from 2 to 20 of the antigenic influenza peptide sequences each covalently attached to a vector.
9. The composition of claim 5 , wherein the composition comprises 5, 6, 7, or 8 of the antigenic influenza peptide sequences each covalently attached to a vector.
10. The composition of claim 5 , further comprising one or more pharmaceutically acceptable carriers, excipients, diluents or adjuvants.
11. The composition of claim 5 , formulated for parenteral, oral, ocular, rectal, nasal, transdermal, topical or vaginal administration.
12. The composition of claim 5 , wherein the composition is in a form of a liquid, emulsion, solid, aerosol or gas.
13. A method of stimulating an immune response, comprising administering the composition of claim 5 to an animal.
14. The method of claim 13 , wherein the animal is a mammal, a bird or a human.
15. A method of preparing a prophylactic or therapeutic pharmaceutical composition comprising combining the composition of claim 5 , with one or more pharmaceutically acceptable carriers, excipients, diluents or adjuvants.